PharmaShots | Incisive News in 3 Shots

Subscribe Now

pfizer

Pfizer to Discontinue Danuglipron’s Development Program for Chronic Weight Management

Pfizer to Discontinue Danuglipron’s Development Program for Chronic Weight Management

April 14, 2025

Pfizer Secures the EC’s Approval for Abrysvo (Respiratory Syncytial Virus Vaccine) for RSV Lower Respiratory Tract Disease

Pfizer Secures the EC’s Approval for Abrysvo (Respiratory Syncytial Virus Vaccine) for RSV Lower Respiratory Tract Disease

April 1, 2025

Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)

February 14, 2025

Pfizer Reports the US FDA Approval of Adcetris Regimen to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Pfizer Reports the US FDA Approval of Adcetris Regimen to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)

February 13, 2025

Pfizer and Astellas Report Follow-up Data from P-III (KEYNOTE-A39/EV-302) Trial of Padcev + Keytruda for Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Pfizer and Astellas Report Follow-up Data from P-III (KEYNOTE-A39/EV-302) Trial of Padcev + Keytruda for Locally Advanced or Metas...

February 12, 2025

Pfizer Reveals Data from P-III (BREAKWATER) trial of Braftovi Regimen in Patients with Metastatic Colorectal Cancer

Pfizer Reveals Data from P-III (BREAKWATER) trial of Braftovi Regimen in Patients with Metastatic Colorectal Cancer

February 4, 2025

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us